Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged material misstatements regarding its drug setrusumab, with a deadline for investors to seek lead plaintiff status set for April 6, 2026 [1] Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025 [1] - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on Osteogenesis Imperfecta patients and downplayed risks associated with its Phase III Orbit study [1] - Defendants are accused of making misleading statements about the company's business and prospects, lacking a reasonable basis for their optimism [1] Group 2: Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing for lead plaintiff status by the April 6, 2026 deadline [1] - Options for investors include retaining counsel or taking no action, with the ability to remain an absent class member [1] - The lead plaintiff will represent all class members and is typically the investor with the largest financial interest [1]

Core Viewpoint - The article discusses a class action lawsuit against BlackRock TCP Capital Corp. due to significant financial losses and misleading statements made by the company regarding its portfolio and net asset value during the class period from November 6, 2024, to January 23, 2026 [1][4]. Financial Performance - On February 27, 2025, BlackRock announced that its portfolio had weakened significantly, with the number of portfolio companies on non-accrual status more than doubling, leading to a 289% increase in debt investments on non-accrual status at cost, rising from 3.7% to 14.4% of the portfolio [2]. - The company's net asset value (NAV) fell by 22.44% year over year to $9.23 per share, with total losses reaching $194,895,042 for the fiscal year, a 186% increase year over year, largely due to a $72.3 million net unrealized loss in the fourth quarter [2]. - On January 23, 2026, BlackRock disclosed that its NAV per share was actually between $7.05 and $7.09, which was 19% lower than the previous quarter and 23.4% lower than the previous year [3]. Lawsuit Details - The class action lawsuit alleges that BlackRock made materially false and misleading statements and failed to disclose adverse facts about its business and operations, including issues with timely valuation of investments and ineffective portfolio restructuring efforts [4]. - The lawsuit claims that these misrepresentations led to an understatement of unrealized losses and an overstatement of NAV, making the company's positive statements about its business misleading [4]. Legal Action - Investors who purchased BlackRock securities during the class period are encouraged to file a lead plaintiff motion by April 6, 2026, to participate in the class action lawsuit [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Plug Power Inc. on behalf of investors who purchased securities between January 17, 2025, and November 13, 2025, alleging misrepresentations regarding a loan from the Department of Energy and the company's ability to construct necessary hydrogen production facilities [1][5]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements about a loan from the Department of Energy and Plug Power's capability to build hydrogen production facilities to access the loan funds [5]. - Investors who purchased Plug Power securities during the specified period and incurred losses are encouraged to consider joining the class action [2][3]. Group 2: Legal Process - Individuals wishing to serve as lead plaintiff must file necessary documents by April 3, 2026, and participation as a lead plaintiff is not required to share in any potential recovery [4]. - All legal representation in this case operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses [4]. Group 3: Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its establishment in 1993 and has a strong track record in class action litigation [6].

New York, New York--(Newsfile Corp. - February 10, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-hea ...

Core Viewpoint - PennyMac Financial Services, Inc. is under investigation for potential violations of federal securities laws related to its mortgage recapture efforts as interest rates declined [1][2][3]. Company Overview - PennyMac originates and services home mortgages and has recently increased its capacity to originate loans to retain borrowers seeking to refinance [2]. - The company has publicly claimed improvements in its recapture rates during this period [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages [3]. Financial Performance - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, revealing that increased origination capacity did not translate into expected refinance business due to heightened competition [4]. - Following the earnings call, PennyMac's stock price dropped over 37%, from $140.70 per share to as low as $93.50 per share [4].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and certain senior executives for securities fraud, following a significant drop in stock price attributed to potential violations of federal securities laws [1][3]. Company Overview - BellRing Brands, Inc. develops, markets, and sells "convenient nutrition" products, primarily known for its ready-to-drink protein shakes under the Premier Protein brand [4]. Allegations of Securities Fraud - The lawsuit claims that BellRing misrepresented sales growth as being driven by increased consumer demand, attributing it to "organic growth" and "strong macro tailwinds," while downplaying competitive pressures [4]. - It is alleged that the actual sales growth was due to key customers stockpiling inventory rather than genuine consumer demand, leading to a subsequent admission of weakened demand due to competitive pressures [4]. Stock Price Decline - On May 6, 2025, BellRing's CFO indicated that several key retailers had reduced their inventory levels, leading to a forecast of low single-digit sales growth for Q3, which resulted in a stock price drop of $14.88 per share, or 19%, from $78.43 to $63.55 [5]. - Following the release of Q3 2025 financial results on August 4, 2025, and a narrowed fiscal year outlook due to increased competition, the stock price fell by $17.46 per share, nearly 33%, from $53.64 to $36.18 on August 5, 2025 [6][7].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock drops linked to potential violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company focused on building large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI workloads [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Performance - Following the announcement that the First Tenant terminated the Advance in Aid of Construction Agreement, Fermi's stock dropped by $5.16 per share, over 33%, from $15.25 to $10.09 on December 12, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure. The company relies on partnerships, including a merger agreement with Core Scientific announced on July 7, 2025 [4]. Allegations of Securities Fraud - The lawsuit claims that CoreWeave misled investors about its ability to meet customer demand and concealed significant construction delays at its data centers, despite assurances of being able to capitalize on unprecedented demand [5]. Stock Performance and Impact - On October 30, 2025, CoreWeave's stock dropped by $8.87 (over 6%) from $139.93 to $131.06 after Core Scientific failed to secure enough shareholder votes for the merger [6]. - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party developer, the stock fell by $17.22 (over 16%) from $105.61 to $88.39 [7]. - A report on December 15, 2025, regarding further delays in a major data center project led to an additional drop of $2.85 (over 3%) from $72.35 to $69.50 [8]. Legal Proceedings - Investors have until March 13, 2026, to request to lead the case in the U.S. District Court for the District of New Jersey, under the case caption Masaitis v. CoreWeave, Inc., et al. [3].

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, which was approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, creating a notable gap between market expectations and internal outlook [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made significant investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - Boston Scientific emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4].

Core Viewpoint - Glancy Prongay Wolke & Rotter LLP has initiated an investigation into Boston Scientific Corporation regarding potential violations of federal securities laws affecting investors [1] Group 1 - The investigation is on behalf of Boston Scientific investors who may have incurred financial losses [1]